<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">35804433</PMID><DateCompleted><Year>2022</Year><Month>07</Month><Day>12</Day></DateCompleted><DateRevised><Year>2022</Year><Month>07</Month><Day>16</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1745-6215</ISSN><JournalIssue CitedMedium="Internet"><Volume>23</Volume><Issue>1</Issue><PubDate><Year>2022</Year><Month>Jul</Month><Day>08</Day></PubDate></JournalIssue><Title>Trials</Title><ISOAbbreviation>Trials</ISOAbbreviation></Journal><ArticleTitle>Amitriptyline at low-dose and titrated for irritable bowel syndrome as second-line treatment (The ATLANTIS trial): protocol for a randomised double-blind placebo-controlled trial in primary care.</ArticleTitle><Pagination><StartPage>552</StartPage><MedlinePgn>552</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">552</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s13063-022-06492-6</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Irritable bowel syndrome (IBS) is a common functional bowel disorder that has a considerable impact on patient quality of life and substantial societal and health care resource costs. Current treatments are often ineffective. Tricyclic antidepressants have shown promise in secondary care populations but their effectiveness in a primary care setting remains unclear.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">ATLANTIS is a randomised, multi-centre, parallel-group, two-arm, double-blind, placebo-controlled trial of low-dose amitriptyline as a second-line treatment for IBS in primary care. Participants will be invited by letter, or recruited opportunistically, from general practices in three regions of England (West Yorkshire, Wessex, and West of England) and screened for eligibility. A total of 518 adult patients with IBS, who are symptomatic despite first-line therapies, will be randomised 1:1 to amitriptyline or identical placebo for 6&#xa0;months. Treatment will commence at a dose of 10&#xa0;mg (or one placebo tablet) daily at night, with dose titration up to a maximum of 30&#xa0;mg at night, depending on side effects and response to treatment. Participant-reported assessments will be conducted at baseline and 3, 6, and 12&#xa0;months post-randomisation. The primary objective is to determine the effectiveness of amitriptyline, compared with placebo, in improving participant-reported global symptoms of IBS at 6&#xa0;months (using the IBS Severity Scoring System). Secondary outcomes include relief of IBS symptoms, effect on IBS-associated somatic symptoms (Patient Health Questionnaire-12), anxiety and depression (Hospital Anxiety and Depression Scale), ability to work and participate in other activities (Work and Social Adjustment Scale), acceptability and tolerability of treatment, self-reported health care use, health-related quality of life (EQ-5D-3L), and cost-effectiveness. A nested, qualitative study will explore patient and general practitioner experiences of treatments and trial participation, including acceptability, adherence, unanticipated effects, and implications for wider use of amitriptyline for IBS in primary care.</AbstractText><AbstractText Label="DISCUSSION" NlmCategory="CONCLUSIONS">Determining the clinical and cost-effectiveness of low-dose amitriptyline as a second-line treatment for IBS in primary care will provide robust evidence to inform management decisions.</AbstractText><AbstractText Label="TRIAL REGISTRATION" NlmCategory="BACKGROUND">ISRCTN ISRCTN48075063 . Registered on 7th June 2019.</AbstractText><CopyrightInformation>&#xa9; 2022. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Alderson</LastName><ForeName>Sarah L</ForeName><Initials>SL</Initials><AffiliationInfo><Affiliation>School of Medicine, Leeds Institute of Health Sciences, University of Leeds, University of Leeds, Room 10.39, Worsley Building, Clarendon Way, Leeds, LS9 9LU, UK. s.l.alderson@leeds.ac.uk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wright-Hughes</LastName><ForeName>Alexandra</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Clinical Trial Research Unit, Leeds Institute of Clinical Trials Research, School of Medicine, University of Leeds, Leeds, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ford</LastName><ForeName>Alexander C</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>Leeds Gastroenterology Institute, St James's University Hospital, Leeds, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Leeds Institute of Medical Research at St. James's, University of Leeds, Leeds, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Farrin</LastName><ForeName>Amanda</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Clinical Trial Research Unit, Leeds Institute of Clinical Trials Research, School of Medicine, University of Leeds, Leeds, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hartley</LastName><ForeName>Suzanne</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Clinical Trial Research Unit, Leeds Institute of Clinical Trials Research, School of Medicine, University of Leeds, Leeds, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fernandez</LastName><ForeName>Catherine</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Clinical Trial Research Unit, Leeds Institute of Clinical Trials Research, School of Medicine, University of Leeds, Leeds, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Taylor</LastName><ForeName>Christopher</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Clinical Trial Research Unit, Leeds Institute of Clinical Trials Research, School of Medicine, University of Leeds, Leeds, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ow</LastName><ForeName>Pei Loo</ForeName><Initials>PL</Initials><AffiliationInfo><Affiliation>Clinical Trial Research Unit, Leeds Institute of Clinical Trials Research, School of Medicine, University of Leeds, Leeds, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Teasdale</LastName><ForeName>Emma</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Centre for Clinical and Community Applications of Health Psychology, School of Psychology, University of Southampton, Southampton, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Howdon</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>School of Medicine, Leeds Institute of Health Sciences, University of Leeds, University of Leeds, Room 10.39, Worsley Building, Clarendon Way, Leeds, LS9 9LU, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guthrie</LastName><ForeName>Elspeth</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>School of Medicine, Leeds Institute of Health Sciences, University of Leeds, University of Leeds, Room 10.39, Worsley Building, Clarendon Way, Leeds, LS9 9LU, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Foy</LastName><ForeName>Robbie</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>School of Medicine, Leeds Institute of Health Sciences, University of Leeds, University of Leeds, Room 10.39, Worsley Building, Clarendon Way, Leeds, LS9 9LU, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ridd</LastName><ForeName>Matthew J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bishop</LastName><ForeName>Felicity L</ForeName><Initials>FL</Initials><AffiliationInfo><Affiliation>Centre for Clinical and Community Applications of Health Psychology, School of Psychology, University of Southampton, Southampton, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Muir</LastName><ForeName>Delia</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Clinical Trial Research Unit, Leeds Institute of Clinical Trials Research, School of Medicine, University of Leeds, Leeds, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chaddock</LastName><ForeName>Matthew</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Let's Cure IBS, Sheffield, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Herbert</LastName><ForeName>Amy</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cooper</LastName><ForeName>Deborah</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>School of Medicine, Leeds Institute of Health Sciences, University of Leeds, University of Leeds, Room 10.39, Worsley Building, Clarendon Way, Leeds, LS9 9LU, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gibbins</LastName><ForeName>Ruth</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Primary Care Research Centre, Faculty of Medicine, University of Southampton, Southampton, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Newman</LastName><ForeName>Sonia</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Primary Care Research Centre, Faculty of Medicine, University of Southampton, Southampton, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cook</LastName><ForeName>Heather</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Exeter Clinical Trials Unit, University of Exeter, Exeter, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Longo</LastName><ForeName>Roberta</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>School of Medicine, Leeds Institute of Health Sciences, University of Leeds, University of Leeds, Room 10.39, Worsley Building, Clarendon Way, Leeds, LS9 9LU, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Everitt</LastName><ForeName>Hazel</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Primary Care Research Centre, Faculty of Medicine, University of Southampton, Southampton, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>16/162/01</GrantID><Agency>Health Technology Assessment Programme</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D000078325">Clinical Trial Protocol</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>07</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Trials</MedlineTA><NlmUniqueID>101263253</NlmUniqueID><ISSNLinking>1745-6215</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>1806D8D52K</RegistryNumber><NameOfSubstance UI="D000639">Amitriptyline</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000639" MajorTopicYN="Y">Amitriptyline</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D043183" MajorTopicYN="Y">Irritable Bowel Syndrome</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015337" MajorTopicYN="N">Multicenter Studies as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011320" MajorTopicYN="N">Primary Health Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Amitriptyline</Keyword><Keyword MajorTopicYN="N">Double-blind</Keyword><Keyword MajorTopicYN="N">Irritable bowel syndrome</Keyword><Keyword MajorTopicYN="N">Placebo</Keyword><Keyword MajorTopicYN="N">Primary care</Keyword><Keyword MajorTopicYN="N">Randomised controlled trial</Keyword></KeywordList><CoiStatement>The authors declare that they have no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>12</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>6</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>7</Month><Day>8</Day><Hour>23</Hour><Minute>49</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>7</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>7</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>7</Month><Day>8</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35804433</ArticleId><ArticleId IdType="pmc">PMC9264306</ArticleId><ArticleId IdType="doi">10.1186/s13063-022-06492-6</ArticleId><ArticleId IdType="pii">10.1186/s13063-022-06492-6</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ford AC, Forman D, Bailey AG, Axon ATR, Moayyedi P. Irritable bowel syndrome: a 10-year natural history of symptoms, and factors that influence consultation behavior. Am J Gastroenterol. 2008;103:1229&#x2013;1239.</Citation><ArticleIdList><ArticleId IdType="pubmed">18371141</ArticleId></ArticleIdList></Reference><Reference><Citation>Oka P, Parr H, Barberio B, Black CJ, Savarino EV, Ford AC. Global prevalence of irritable bowel syndrome according to Rome III or IV criteria: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2020;5:908&#x2013;917.</Citation><ArticleIdList><ArticleId IdType="pubmed">32702295</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson WG, Heaton KW, Smyth GT, Smyth C. Irritable bowel syndrome: the view from general practice. Eur J Gastroenterol Hepatol. 1997;9:689&#x2013;692.</Citation><ArticleIdList><ArticleId IdType="pubmed">9262978</ArticleId></ArticleIdList></Reference><Reference><Citation>Pace F, Molteni P, Bollani S, Sarzi-Puttini P, Stockbrugger R, Bianchi Porro G, et al. Inflammatory bowel disease versus irritable bowel syndrome: a hospital-based, case-control study of disease impact on quality of life. Scand J Gastroenterol. 2003;38:1031&#x2013;1038.</Citation><ArticleIdList><ArticleId IdType="pubmed">14621276</ArticleId></ArticleIdList></Reference><Reference><Citation>Frandemark A, Tornblom H, Jakobsson S, Simren M. Work productivity and activity impairment in irritable bowel syndrome (IBS): a multifaceted problem. Am J Gastroenterol. 2018;113:1540&#x2013;1549.</Citation><ArticleIdList><ArticleId IdType="pubmed">30254230</ArticleId></ArticleIdList></Reference><Reference><Citation>Hookway C, Buckner S, Crosland P, Longson D. Irritable bowel syndrome in adults in primary care: summary of updated NICE guidance. BMJ. 2015;350:h701.</Citation><ArticleIdList><ArticleId IdType="pubmed">25716701</ArticleId></ArticleIdList></Reference><Reference><Citation>Shivaji UN, Ford AC. Prevalence of functional gastrointestinal disorders among consecutive new patient referrals to a gastroenterology clinic. Front Gastroenterol. 2014;5:266&#x2013;271.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5369735</ArticleId><ArticleId IdType="pubmed">28839783</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang L, Chey WD, Harris L, Olden K, Surawicz C, Schoenfeld P. Incidence of ischemic colitis and serious complications of constipation among patients using alosetron: systematic review of clinical trials and post-surveillance marketing data. Am J Gastroenterol. 2006;101:1069&#x2013;1079.</Citation><ArticleIdList><ArticleId IdType="pubmed">16606352</ArticleId></ArticleIdList></Reference><Reference><Citation>Black CJ, Burr NE, Ford AC. Relative efficacy of tegaserod in a systematic review and network meta-analysis of licensed therapies for irritable bowel syndrome with constipation. Clin Gastroenterol Hepatol. 2020;18:1238&#x2013;9.e1.</Citation><ArticleIdList><ArticleId IdType="pubmed">31302307</ArticleId></ArticleIdList></Reference><Reference><Citation>Sindrup SH, Otto M, Finnerup NB, Jensen TS. Antidepressants in the treatment of neuropathic pain. Basic Clin Pharmacol Toxicol. 2005;96:399&#x2013;409.</Citation><ArticleIdList><ArticleId IdType="pubmed">15910402</ArticleId></ArticleIdList></Reference><Reference><Citation>Talley NJ, Locke GR, Saito YA, Almazar AE, Bouras EP, Howden CW, et al. Effect of amitriptyline and escitalopram on functional dyspepsia: a multi-center, randomized, controlled study. Gastroenterol. 2015;149:340&#x2013;349.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4516571</ArticleId><ArticleId IdType="pubmed">25921377</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong J, Motulsky A, Abrahamowicz M, Eguale T, Buckeridge DL, Tamblyn R. Off-label indications for antidepressants in primary care: descriptive study of prescriptions from an indication based electronic prescribing system. BMJ. 2017;356:j603.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5320934</ArticleId><ArticleId IdType="pubmed">28228380</ArticleId></ArticleIdList></Reference><Reference><Citation>Saarto T, Wiffen PJ. Antidepressants for neuropathic pain. Cochrane Database Syst Rev. 2007;Issue 4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10576544</ArticleId><ArticleId IdType="pubmed">17943857</ArticleId></ArticleIdList></Reference><Reference><Citation>Gorard DA, Libby GW, Farthing MJ. Influence of antidepressants on whole gut orocaecal transit times in health and irritable bowel syndrome. Aliment Pharmacol Ther. 1994;8:159&#x2013;166.</Citation><ArticleIdList><ArticleId IdType="pubmed">8038347</ArticleId></ArticleIdList></Reference><Reference><Citation>Gorard DA, Libby GW, Farthing MJ. Effect of a tricyclic antidepressant on small intestinal motility in health and diarrhea-predominant irritable bowel syndrome. Dig Dis Sci. 1995;40:86&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pubmed">7821126</ArticleId></ArticleIdList></Reference><Reference><Citation>Shivaji UN, Ford AC. Beliefs about management of irritable bowel syndrome in primary care: cross-sectional survey in one locality. Prim Health Care Res Dev. 2014;16:263&#x2013;269.</Citation><ArticleIdList><ArticleId IdType="pubmed">25287958</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruepert L, Quartero AO, de Wit NJ, van der Heijden GJ, Rubin G, Muris JW. Bulking agents, antispasmodics and antidepressants for the treatment of irritable bowel syndrome. Cochrane Database Syst Rev. 2011;2011(8):CD003460.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8745618</ArticleId><ArticleId IdType="pubmed">21833945</ArticleId></ArticleIdList></Reference><Reference><Citation>Ford AC, Lacy BE, Harris LA, Quigley EM, Moayyedi P. Effect of antidepressants and psychological therapies in irritable bowel syndrome: an updated systematic review and meta-analysis. Am J Gastroenterol. 2019;114:21&#x2013;39.</Citation><ArticleIdList><ArticleId IdType="pubmed">30177784</ArticleId></ArticleIdList></Reference><Reference><Citation>Black CJ, Yuan Y, Selinger CP, Camilleri M, Quigley EMM, Moayyedi P, et al. Efficacy of soluble fibre, antispasmodic drugs, and gut-brain neuromodulators in irritable bowel syndrome: a systematic review and network meta-analysis. Lancet Gastroenterol Hepatol. 2020;5:117&#x2013;131.</Citation><ArticleIdList><ArticleId IdType="pubmed">31859183</ArticleId></ArticleIdList></Reference><Reference><Citation>Vahedi H, Merat S, Momtahen S, Kazzazi AS, Ghaffari N, Olfati G, et al. Clinical trial: the effect of amitriptyline in patients with diarrhea-predominant irritable bowel syndrome. Aliment Pharmacol Ther. 2008;27:678&#x2013;684.</Citation><ArticleIdList><ArticleId IdType="pubmed">18248658</ArticleId></ArticleIdList></Reference><Reference><Citation>Oh SJ, Takakura W, Rezaie A. Shortcomings of trials assessing antidepressants in the management of irritable bowel syndrome: a critical review. J Clin Med. 2020;9:2933.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7564007</ArticleId><ArticleId IdType="pubmed">32932856</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaminski A, Kamper A, Thaler K, Chapman A, Gartlehner G. Antidepressants for the treatment of abdominal pain-related functional gastrointestinal disorders in children and adolescents. Cochrane Database Syst Rev. 2011;2011(7):CD008013.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6769179</ArticleId><ArticleId IdType="pubmed">21735420</ArticleId></ArticleIdList></Reference><Reference><Citation>Francis CY, Morris J, Whorwell PJ. The irritable bowel severity scoring system: a simple method of monitoring irritable bowel syndrome and its progress. Aliment Pharmacol Ther. 1997;11:395&#x2013;402.</Citation><ArticleIdList><ArticleId IdType="pubmed">9146781</ArticleId></ArticleIdList></Reference><Reference><Citation>Muller-Lissner S, Koch G, Talley NJ, Drossman D, Rueegg P, Dunger-Baldauf C, et al. Subject&#x2019;s Global Assessment of Relief: an appropriate method to assess the impact of treatment on irritable bowel syndrome-related symptoms in clinical trials. J Clin Epidemiol. 2003;56:310&#x2013;316.</Citation><ArticleIdList><ArticleId IdType="pubmed">12767407</ArticleId></ArticleIdList></Reference><Reference><Citation>Kroenke K, Spitzer RL, Williams JBW. The PHQ-15: validity of a new measure for evaluating the severity of somatic symptoms. Psychosom Med. 2002;64:258&#x2013;266.</Citation><ArticleIdList><ArticleId IdType="pubmed">11914441</ArticleId></ArticleIdList></Reference><Reference><Citation>Spiller RC, Humes DJ, Campbell E, Hastings M, Neal KR, Dukes GE, et al. The Patient Health Questionnaire 12 Somatic Symptom scale as a predictor of symptom severity and consulting behaviour in patients with irritable bowel syndrome and symptomatic diverticular disease. Aliment Pharmacol Ther. 2010;32:811&#x2013;820.</Citation><ArticleIdList><ArticleId IdType="pubmed">20629976</ArticleId></ArticleIdList></Reference><Reference><Citation>Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67:361&#x2013;370.</Citation><ArticleIdList><ArticleId IdType="pubmed">6880820</ArticleId></ArticleIdList></Reference><Reference><Citation>Mundt JC, Marks IM, Shear MK, Greist JH. The Work and Social Adjustment Scale: a simple measure of impairment in functioning. Br J Psychiatry. 2002;180:461&#x2013;464.</Citation><ArticleIdList><ArticleId IdType="pubmed">11983645</ArticleId></ArticleIdList></Reference><Reference><Citation>Kennedy T, Jones R, Darnley S, Seed P, Wessely S, Chalder T. Cognitive behaviour therapy in addition to antispasmodic treatment for irritable bowel syndrome in primary care: randomised controlled trial. BMJ. 2005;331:435&#x2013;437.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1188111</ArticleId><ArticleId IdType="pubmed">16093252</ArticleId></ArticleIdList></Reference><Reference><Citation>Moss-Morris R, McAlpine L, Didsbury LP, Spence MJ. A randomized controlled trial of a cognitive behavioural therapy-based self-management intervention for irritable bowel syndrome in primary care. Psychol Med. 2010;40:85&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pubmed">19531276</ArticleId></ArticleIdList></Reference><Reference><Citation>Uher R, Farmer A, Henigsberg N, Rietschel M, Mors O, Maier W, et al. Adverse reactions to antidepressants. Br J Psychiatry. 2009;195:202&#x2013;210.</Citation><ArticleIdList><ArticleId IdType="pubmed">19721108</ArticleId></ArticleIdList></Reference><Reference><Citation>Group E EuroQol&#x2013;a new facility for the measurement of health-related quality of life. Health Policy. 1990;16:199&#x2013;208.</Citation><ArticleIdList><ArticleId IdType="pubmed">10109801</ArticleId></ArticleIdList></Reference><Reference><Citation>Bushnell DM, Martin ML, Ricci JF, Bracco A. Performance of the EQ-5D in patients with irritable bowel syndrome. Value Health. 2006;9:90&#x2013;97.</Citation><ArticleIdList><ArticleId IdType="pubmed">16626412</ArticleId></ArticleIdList></Reference><Reference><Citation>May C, Finch T, Mair F, Ballini L, Dowrick C, Eccles M, et al. Understanding the implementation of complex interventions in health care: the normalization process model. BMC Health Serv Res. 2007;7:148.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2089069</ArticleId><ArticleId IdType="pubmed">17880693</ArticleId></ArticleIdList></Reference><Reference><Citation>Leventhal H, Phillips LA, Burns E. The common-sense model of self-regulation (CSM): a dynamic framework for understanding illness self-management. J Behav Med. 2016;39:935&#x2013;946.</Citation><ArticleIdList><ArticleId IdType="pubmed">27515801</ArticleId></ArticleIdList></Reference><Reference><Citation>Harvey JM, Sibelli A, Chalder T, Everitt H, Moss-Morris R, Bishop FL. Desperately seeking a cure: treatment seeking and appraisal in irritable bowel syndrome. Br J Health Psychol. 2018;23:561&#x2013;579.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6175452</ArticleId><ArticleId IdType="pubmed">29508539</ArticleId></ArticleIdList></Reference><Reference><Citation>Everitt H, Landau S, Little P, Bishop FL, McCrone P, O'Reilly G, et al. Assessing Cognitive behavioural Therapy in Irritable Bowel (ACTIB): protocol for a randomised controlled trial of clinical-effectiveness and cost-effectiveness of therapist delivered cognitive behavioural therapy and web-based self-management in irritable bowel syndrome in adults. BMJ Open. 2015;5:e008622.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4513538</ArticleId><ArticleId IdType="pubmed">26179651</ArticleId></ArticleIdList></Reference><Reference><Citation>Sisson G, Ayis S, Sherwood RA, Bjarnason I. Randomised clinical trial: a liquid multi-strain probiotic vs. placebo in the irritable bowel syndrome&#x2013;a 12 week double-blind study. Aliment Pharmacol Ther. 2014;40:51&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pubmed">24815298</ArticleId></ArticleIdList></Reference><Reference><Citation>Peckham EJ, Relton C, Raw J, Walters C, Thomas K, Smith C, et al. Interim results of a randomised controlled trial of homeopathic treatment for irritable bowel syndrome. Homeopathy. 2014;103:172&#x2013;177.</Citation><ArticleIdList><ArticleId IdType="pubmed">24931748</ArticleId></ArticleIdList></Reference><Reference><Citation>Everitt HA, Landau S, O'Reilly G, Sibelli A, Hughes S, Windgassen S, et al. Assessing telephone-delivered cognitive-behavioural therapy (CBT) and web-delivered CBT versus treatment as usual in irritable bowel syndrome (ACTIB): a multicentre randomised trial. Gut. 2019;68:1613&#x2013;1623.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6709776</ArticleId><ArticleId IdType="pubmed">30971419</ArticleId></ArticleIdList></Reference><Reference><Citation>Black CJ, Burr NE, Camilleri M, Earnest DL, Quigley EM, Moayyedi P, et al. Efficacy of pharmacological therapies in patients with IBS with diarrhoea or mixed stool pattern: Systematic review and network meta-analysis. Gut. 2020;69:74&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pubmed">30996042</ArticleId></ArticleIdList></Reference><Reference><Citation>Black CJ, Burr NE, Quigley EMM, Moayyedi P, Houghton LA, Ford AC. Efficacy of secretagogues in patients with irritable bowel syndrome with constipation: systematic review and network meta-analysis. Gastroenterol. 2018;155:1753&#x2013;1763.</Citation><ArticleIdList><ArticleId IdType="pubmed">30144426</ArticleId></ArticleIdList></Reference><Reference><Citation>Braun V, Clarke V. Using thematic analysis in psychology. Qual Res Psychol. 2006;3:77&#x2013;101.</Citation></Reference><Reference><Citation>Corbin J, Strauss A. Basics of qualitative research (3rd ed.): techniques and procedures for developing grounded theory. Thousand Oaks, California;&#xa0;2008.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>